Which class of antihypertensive drugs does Aprecitentan (Tryvio) belong to?

Aprocitentan-Tryvio is a new antihypertensive drug that has attracted much attention in recent years. Its mechanism of action is different from traditional diuretics, calcium channel blockers or beta-blockers. It is an endothelin receptor antagonist (Endothelin Receptor Antagonist, ERA), which mainly exerts antihypertensive effects by inhibiting the endothelin-1 pathway.

Endothelin-1 is a potent vasoconstrictor that plays an important role in the development of hypertension and cardiovascular disease. Traditional antihypertensive drugs mainly work by dilating blood vessels, diuresis and natriuresis, or inhibiting the sympathetic nervous system, while aprecitentan blocks endothelin receptors and directly intervenes in the regulation of vascular tone, thereby reducing peripheral resistance and achieving a long-lasting and stable antihypertensive effect.

Aprecitentan has shown potential advantages over commonRAAS inhibitors or calcium antagonists in some patients with refractory or resistant hypertension. Due to its unique mechanism, it can be used in combination with other antihypertensive drugs to supplement pathways that cannot be covered by traditional regimens and further improve blood pressure control rates. For patients whose blood pressure cannot reach target for a long time, adding aprecitentan may bring about a more significant antihypertensive effect.

At present, aprecitentan still belongs to a newer drug class, and multiple clinical studies around the world have shown that it can not only lower blood pressure, but may also reduce the risk of hypertension-related complications, especially in the prevention of stroke and myocardial infarction. Although it is not yet on the market in China, judging from the attention in academic and clinical fields, this type of drug is considered an important supplement for the treatment of hypertension in the future. As an innovative endothelin receptor antagonist antihypertensive drug, it provides a new option for the treatment of resistant hypertension.

Reference materials:https://go.drugbank.com/drugs/DB15059